Congratulations to @isth.org Councilor @middeldorps.bsky.social on being named & delivering the 2025 Sol Sherry Disting. Lecture in Thrombosis @ the recent @americanheart.bsky.social Scientific Sessions recognizing her role as a foremost clinician & researcher in the field of CV disease & stroke!

📰 Check it out! The @ash.hematology.org and ISTH Updated Guidelines on the Treatment of Pediatric VTE are featured in Hematology Advisor. Don’t miss this spotlight on our collaborative effort! 📖 Read the full feature: www.hematologyadvisor.com/news/pediatr... #PediatricVTE #Hematology #ISTH

ASH and ISTH Update Guidelines on Treatment of Pediatric VTE

The ASH and ISTH updated guidelines for treatment of pediatric venous thromboembolism, focusing on improved outcomes and patient quality of life.

hematologyadvisor.com

What an inspiring #ISTH2025! It was wonderful to host the global #thrombosis & #hemostasis community in DC. From the latest science & innovations to networking & building new collabs - it had it all! Look out for recordings & other post- @isth.org congress updates. Goodbye & see you @ #ISTH2026!

#ISTH2025

Saskia Middeldorp@middeldorps.bsky.social · last yr.

Marc Rodger highlighting the #Highlow study and providing guidance on how to implement the results 👌🏼

Marc Rodger highlighting the #Highlow study and providing guidance on how to implement the results 👌🏼

Now my favourite topic presented eloquently by prof Marc Rodger. Answering all the questions needed for providing well-informed information to your patients. Put the #LMWH needles away in patients with placenta-mediated complications in inherited #thrombophilia! #AFFIRM #ALIFE2 #ISTH2025

It took 7 years to recruit 51 patients for the IMPACT single-arm study on certiluzomab on top of LMWH-aspirin shows adverse outcome in 20% which is lower than non-contemporary controls. #ISTH2025

More on pregnancy and #APS, now from obstetric perspective. Only 1% of recurrent miscarriage patients had APS antibodies, similar to controls. #ISTH2025

Implementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸 @marycushmanmd.bsky.social

Why do we have so little data on pregnancy and thrombotic outcomes in #APS?? Well-illustrated by State-of-the-Art lecture by dr Karen Breen. We MUST do better! #ISTH2025

📣 ARIVA Trial at #ISTH2025: 🧪 First RCT on antithrombotic therapy post-venous stenting for PTS 🔵 6-month primary patency rate was higher than expected 💊 No added benefit of aspirin + rivaroxaban vs. rivaroxaban alone www.ahajournals.org/doi/10.1161/...

Meta-analysis on GLP-1RA (vs. placebo) and VTE: 🔹 PE rates significantly lower 📉 🔹 VTE rates lower but not statistically significant 🔹 No difference in DVT 🔹 Study design matters: RCTs vs. observational data Accepted for publication in JTH! #ISTH2025 #VTE #GLP1RA #Thrombosis @jthjournal.bsky.social

It’s really worth stopping by our @isth.org booth and get inspired for next year’s meeting in….. Paris! #ISTH2025

What started as strong Mendelian observations, has now evolved to a strongly polygenenic etiology of #VTE. Inside and outside the coagulation cascade. #ISTH2025

There is more to established #thrombophilia defects in understanding the genetics of venous thromboembolism #VTE. Plenary lecture by Prof Pierre Morange #ISTH2025

Tips for asking ?s as moderator #ISTH2025 Clinical talk: what future directions do you see this work taking? Basic science: how do you envision this translating to the clinic? Next level pro tip: contact author beforehand to see what they didn’t have time to present that they’d like you to ask

Adjust-DVT study. Only 5% of patients with suspected #DVT had an age-adjusted d-dimer that omits the need for compression ultrasound. I don’t think it is worth it. What do you think? #ISTH2025

This is why diagnosing, treating and investigating #APS is so complicated. Massive differences in classification between Sydney 2006 and ACR/EULAR 2023. Only 40% of patients fulfilled the new criteria. What are the implications for future research? #ISTH2025

The effects of andexanet on enoxaparin are in line with effects on oral factorXa inhibitors. Great presentation by PhD student Thijs van Haaps #ISTH2025

Excellent points ⬇️ Exclusion of pregnant people from trials leads to paradoxical effects! #ISTH2025

State-of-the-Art talk bij de Luuk Scheres Despite hormone use being the most prevalent and important risk factor for #VTE in women <50, there is huge underrepresentation of risk models and funding. Food for thought and action 💪🏼 #ISTH2025

There is still taboo about discussing menstruation 🩸 There are differences between assessment of abnormal uterine bleeding between professional societies. This is important to realisme and underscores the need to collaborate multidisciplinary. Dr Roseline d’Oiron #ISTH2025

Even if you are not a pediatrician, you can learn so much. Beautiful slides on thrombolysis 🤩 Dr Irene Klaassen #ISTH2025

Good morning everyone! Another exciting day ahead #ISTH2025. Thirty years ago I visited my first @isth.org Congress. 📣 This morning, I can switch sessions to see two of my former PhD students shine in State-of-the-Art sessions. We take good care of the next generation @isth.org!

Interesting data on influence of race from the RIETE registry. After correction for treatment etc, these differences did not show in multi-variate analysis. #ISTH2025

VTE isn’t “over” at discharge. Many patients face lasting symptoms & distress. 🗣️ PROMs help reveal what matters, if we use them right. ✅ Ask ✅ Act ✅ Guide care Structured models like Attend-PE show the way. #ISTH2025 #Thrombosis #PatientVoice

Dragons’s Den of the highly fruitful www.invent-vte.com netwerk. Collaboration leads to practice-changing trials!! #ISTH2025

This is what we were waiting for. A direct comparison between apixaban and rivaroxaban for the treatment of acute VTE. Apixaban reduces bleeding risk in the first 3 months by >50%! Practice changing investigator-initiated RCT. #ISTH2025

What a fantastic plenary lecture by Prof Jennifer Curnow - in loving and admiring memory of my dear friend Dr Claire McLintock. #ISTH2025

Kicking off #ISTH2025 with the first falk from RSCI by @aislingrehill.bsky.social on fibrin on trained immunity-associated myeloid cell hypercoagulability @rogerpreston.bsky.social @rcsi.bsky.social